Cancer vaccines have gained much interest among scientists but face a number of hurdles. A new mRNA vaccine for glioma offers a step forward in training the immune system to fight cancer.
myNEO Therapeutics to focus on building proprietary product pipeline based on a novel class of shared therapeutic cancer targets derived from the dark genome named “camyotopes” Lead product CAMYO-01 incorporates a pool of colorectal cancer-specific camyotopes formulated into an mRNA-based vaccineCAMYO-01 is advancing towards clinical development for the treatment of colorectal cancer GHENT, Belgium – October 25th 2023. myNEO, a biotech company focused on exploiting “dark genome” targets to devel
Investegate announcements from Biognosys AG, Biognosys Presenting Novel Cancer Research on its Proteomics Platforms and Advancing Data Analysis with the Launch of Proteoverse™ at the AACR Annual Meeting 2023
In collaboration with prominent biopharma companies and academic institutions, Biognosys will demonstrate the technological advances and versatility of the TrueDiscovery, TrueTarget, and TrueSignature
Data from Biognosys and its collaborators demonstrate the technological advances and utility of their proteomics platforms in oncology R&D and clinical settings Biognosys, a leader in next-generation